Back to School: How biopharma can reboot drug development. Access exclusive analysis here
In an international Phase III study in 424 patients, 69% and 56% of patients receiving Erbitux plus
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury